

Economic Plan

This document identifies the areas prioritised for de Novo economic analysis. The final analysis may differ from those described below. The rationale for any differences will be explained in the guideline

1 Guideline

Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young people and adults (Hepatitis B (chronic))

2 List of Modelling Questions

Clinical questions by scope area	<p>In people with Chronic Hepatitis B (CHB), what is the clinical and cost effectiveness of pharmacological therapies used alone and in combination in achieving remission of the activity of CHB?</p> <p>In people with CHB, what is the clinical and cost effectiveness of sequential drug therapy (add-on or switching) in achieving remission of the activity of CHB?</p>
Population	<p>Individuals with chronic hepatitis B. Separate consideration for the following subgroups:</p> <ul style="list-style-type: none"> • HBeAg positive CHB • HBeAg negative CHB
Interventions considered for inclusion	<p>Sequences including</p> <ul style="list-style-type: none"> • No treatment (natural history) • Pegylated interferon alfa 2a • Tenofovir • Entecavir • Relevant combinations of above drugs
Type of analysis	Cost Utility Analysis
Clinical questions by scope area	<p>What is the clinical and cost-effectiveness of genotypic testing in determining which antiviral treatment to offer people with CHB?</p>
Population	<p>Individuals with chronic hepatitis B, stratified according to genotype A through H (if data allows) with special consideration for the following subgroups:</p> <ul style="list-style-type: none"> • HBeAg positive CHB • HBeAg negative CHB
Interventions considered	<ul style="list-style-type: none"> • All patients undergo genotype testing prior to treatment initiation and treatment is tailored accordingly • No patients undergo genotype testing prior to treatment

for inclusion	initiation
Type of analysis	Cost Utility Analysis
Clinical questions by scope area	In people with CHB with cirrhosis, including those with liver decompensation, what is the clinical and cost effectiveness of antiviral treatment to prevent reactivation and liver transplantation?
Population	People with chronic hepatitis B and decompensated liver disease. The clinical evidence does not subgroup populations by HBeAg status; therefore, the population in the model is likely to be mixed according to the baseline characteristics of the trial data.
Interventions considered for inclusion	<ul style="list-style-type: none"> • No treatment (natural history) • Adefovir • Tenofovir • Entecavir • Tenofovir+Emtricitabine
Type of analysis	Cost Utility Analysis